Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.

Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups.

Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15.

PMID:
25975975
2.

Occlusive vasculopathy due to type I cryoglobulinemia in IgG-lambda type multiple myeloma.

Jiménez-Gallo D, Albarrán-Planelles C, de la Varga-Martínez R, Capote FJ, Guerrero-Sánchez F, Linares-Barrios M.

Rev Clin Esp. 2015 Jun-Jul;215(5):e39-42. doi: 10.1016/j.rce.2015.01.014. Epub 2015 Mar 3. English, Spanish. No abstract available.

PMID:
25743167
3.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators.

N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096.

4.

Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.

Carrillo-Cruz E, Marín-Oyaga VA, Solé Rodríguez M, Borrego-Dorado I, de la Cruz Vicente F, Quiroga Cantero E, Manzanares Pérez M, Capote FJ, Ramírez Sánchez MJ, Espigado Tocino I, Pérez-Vega H, Vázquez-Albertino R, Pérez-Simón JA.

Eur J Haematol. 2015 Jan;94(1):23-30. doi: 10.1111/ejh.12284.

PMID:
24520874
5.

Lymphocytic lymphoma/chronic lymphocytic leukemia in a solid-organ donor: an unestablished risk in elderly donors.

Collantes R, Mazuecos A, Garcia T, Gomez-Bravo MA, Pascasio JM, Capote FJ, Castro P.

Transplantation. 2013 Aug 15;96(3):e14-5. doi: 10.1097/TP.0b013e3182997d11. No abstract available.

PMID:
23917688
6.

Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).

Jarque I, Tormo M, Bello JL, Rovira M, Batlle M, Julià A, Tabares S, Rivas C, Fernández-Sevilla A, García-Boyero R, Debén G, González-Campos J, Capote FJ, Sanz MA; Spanish Pethema Group.

Med Mycol. 2013 Feb;51(2):150-4. doi: 10.3109/13693786.2012.693213. Epub 2012 Jun 19.

PMID:
22712457
7.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators.

N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. Erratum in: N Engl J Med. 2012 Jul 19;367(3):285.

8.

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17.

9.

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8.

10.

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups.

Blood. 2010 Jun 24;115(25):5137-46. doi: 10.1182/blood-2010-01-266007. Epub 2010 Apr 14.

11.

[Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group].

García-Sanz R, Alegre A, Capote FJ, Hernández JM, Rosiñol L, Rubia Jde L, Sureda A, Arriba Fd, Bargay J, Díaz Mediavilla J, García-Laraña J, Lahuerta JJ, Mateos MV, Prósper F, San Miguel J, Bladé J; Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología.

Med Clin (Barc). 2010 Mar 6;134(6):268-78. doi: 10.1016/j.medcli.2009.07.040. Epub 2009 Oct 28. Review. Spanish. No abstract available.

PMID:
19863972
12.

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.

González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF; GEL/TAMO (Grupo Español de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas).

Haematologica. 2007 Nov;92(11):1489-94.

13.

Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.

Ortega JJ, Madero L, Martín G, Verdeguer A, García P, Parody R, Fuster J, Molines A, Novo A, Debén G, Rodríguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, González JD, Bolufer P, González M, Sanz MA; PETHEMA Group.

J Clin Oncol. 2005 Oct 20;23(30):7632-40.

PMID:
16234524
14.

[HIV-2 and HTLV-I/II infections in Spain].

Toro C, Rodés B, Aguilera A, Caballero E, Benito R, Bassani S, Rodríguez C, Tuset C, Ortiz de Lejarazu R, Eirós J, García J, Calderón E, Capote FJ, Vallejo A, Gutiérrez M, Soriano V; Grupo Español para el Estudio del VIH-2 y del HTLV-I/II.

Enferm Infecc Microbiol Clin. 2004 Mar;22(3):177-82. Spanish.

PMID:
14987538
15.

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.

Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas.

Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23.

16.

Cosmopolitan HTLV-Ia subtype among Spanish native patients.

Vallejo A, Capote FJ, Guisado F, Leal M, Calderón E.

AIDS Res Hum Retroviruses. 2003 Jul;19(7):609-11.

PMID:
12921092
17.

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.

Sanz MA, López J, Lahuerta JJ, Rovira M, Batlle M, Pérez C, Vázquez L, Julià A, Palau J, Gutiérrez M, Capote FJ, Ramos F, Benlloch L, Larrea L, Jarque I; Spanish PETHEMA Group.

J Antimicrob Chemother. 2002 Jul;50(1):79-88.

PMID:
12096010
18.

Primary lymphoma of the central nervous system and HTLV-I infection.

Calderón EJ, Japón MA, Chinchón I, Soriano V, Capote FJ.

Haematologia (Budap). 2002;31(4):365-7.

PMID:
12038521
19.

Identification of two atypical PML-RAR(alpha) transcripts in two patients with acute promyelocytic leukemia.

Barragán E, Bolufer P, Martín G, Cervera J, Moreno I, Capote FJ, Rosique P, Sanz MA.

Leuk Res. 2002 May;26(5):439-42.

PMID:
11916515
20.

Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.

González M, Barragán E, Bolufer P, Chillón C, Colomer D, Borstein R, Calasanz MJ, Gómez-Casares MT, Villegas A, Marugán I, Román J, Martín G, Rayón C, Debén G, Tormo M, Díaz-Mediavilla J, Esteve J, González-San Miguel J, Rivas C, Pérez-Equiza K, García-Sanz R, Capote FJ, Ribera JM, Arias J, León A, Sanz MA; Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group.

Br J Haematol. 2001 Jul;114(1):99-103.

PMID:
11472351

Supplemental Content

Loading ...
Support Center